KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: A double-blind, randomized, placebo-controlled phase 3 study Meeting Abstract


Authors: Chung, H.; Bang, Y.; Fuchs, C.; Qin, S.; Satoh, T.; Shitara, K.; Tabernero, J.; Van Cutsem, E.; Cao, Z.; Chen, X.; Kang, S.; Shih, C.; Janjigian, Y.
Abstract Title: KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: A double-blind, randomized, placebo-controlled phase 3 study
Meeting Title: ESMO 21st World Congress on Gastrointestinal Cancer
Journal Title: Annals of Oncology
Volume: 30
Issue: Suppl. 4
Meeting Dates: 2019 Jul 3-6
Meeting Location: Barcelona, Spain
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2019-07-01
Start Page: mdz155.093
Language: English
ACCESSION: WOS:000475860200113
DOI: 10.1093/annonc/mdz155.093
PROVIDER: wos
Notes: Meeting Abstract: P-094 -- Appears on page iv25 of the abstract book -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Yelena Yuriy Janjigian
    394 Janjigian